Extracellular vesicles (EVs) are lipid‐membrane enclosed nanoparticles that play significant
roles in health and disease. EVs are abundant in body fluids and carry an array of molecules …

Many macromolecular therapeutics could potentially treat genetic disorders and cancer.
They have, however, not yet reached the clinical stage owing to a lack of suitable carriers …

Encapsulation of antibiotics into nanoparticles is a potential strategy to eradicate biofilms. To
allow further optimization of nanomedicines for biofilm eradication, the influence of the …

Obtaining sub‐resolution particle positions in fluorescence microscopy images is essential
for single particle tracking and high‐resolution localization microscopy. While the …

The local delivery of small interfering RNA (siRNA) to the lungs may provide a therapeutic
solution to a range of pulmonary disorders. Resident alveolar macrophages (rAM) in the …

Intravenous administration of siRNA nanocarriers may provide unique therapeutic
opportunities for tissue-specific gene silencing. Although often engineered to overcome the …

Cell-derived membrane vesicles that are released in biofluids, like blood or saliva, are
emerging as potential non-invasive biomarkers for diseases, such as cancer. Techniques …

The treatment of Stenotrophomonas maltophilia infection with β-lactam antibiotics leads to
increased release of outer membrane vesicles (OMVs), which are packed with two …

Measuring the concentration of Nanomaterials (NMs) is a key to understanding NM fate,
behaviour, exposure and risk. This chapter discusses three most commonly measured …

The corona phase—the adsorbed layer of polymer, surfactant, or stabilizer molecules
around a nanoparticle—is typically utilized to disperse nanoparticles into a solution or solid …